Gyre Therapeutics, Inc.
GYREBiotechnology
$4.56−28.94%As of Oct 30vs prior close
- Market cap
- $483M
- P/E (TTM)
- –
- From 52W high
- −48.00%
- EPS (LTM)
- -$0.17
- Revenue (LTM)
- $116.4M
- Net margin
- -22.05%
Nomior Score
48
Steady ProfileSpeculativeBottom 46% of the scored universe
Growth47
Quality68
Value54
Momentum40
Resilience39
Growth
+80.87%revenue a year over 8 fiscal years
YE17 $1MLTM $116.4M
Connections
Revenue to profitQ2 YE26
The operating loss was 49% of revenue, wider by 42 pts on a year.
Who owns it
2funds